Navigation Links
First urine-based cancer mutation monitoring test available from Trovagene

SAN DIEGO, Oct. 1, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced availability of the first urine test for cancer mutation monitoring through the company's CLIA laboratory. The robustness of Trovagene's ultra-sensitive assay procedure has been demonstrated for detection of the BRAF V600E mutation from cell-free DNA in urine.  This mutation commonly occurs in melanoma, as well as several other prevalent cancer types.


Of the more than 70,000 cases of melanoma diagnosed each year in the United States, up to 70 percent harbor a BRAF-type mutation and of these, 80 percent may be positive specifically for BRAF V600E.1 There are several FDA-approved targeted therapies for the treatment of BRAF-positive melanoma, making mutational status monitoring an area of clinical interest among treating physicians.

Trovagene's cell-free BRAFSM test is a laboratory-developed test (LDT) designed to detect and monitor this mutation in metastatic cancer patients with biopsy-proven V600E BRAF mutation in their tumor.  It is the first commercial assay within Trovagene's cancer monitoring portfolio performed using a droplet digital PCR (ddPCR) platform.  Using urine as a non-invasive, systemic sample, the cell-free BRAF test could help physicians monitor changes in mutation status for patients requiring therapy for cancers that have this mutation. For patients with difficult-to-biopsy metastatic tumors, urine-based mutation testing may also provide a viable alternative to check mutation status as part of the initial treatment workup.

"We are developing a systemic, non-invasive cancer monitoring system," said Mark Erlander, Ph.D., chief scientific officer for Trovagene. "Traditionally, the mutation status of a tumor is determined using a tissue sample – a method that has limited practicality for patient monitoring due to costs, tumor heterogeneity and potential complications from the biopsy process. The ability to detect the mutation signal in cell-free DNA isolated from urine overcomes this limitation and meets a significant technical and clinical need."

The cell-free BRAF mutation assay has been tested across a range of solid tumors including melanoma, non-small cell lung, rectal, and colon cancers, indicating that urine-based mutation detection is applicable across many cancer types.  Additional clinical studies are ongoing to further understand the full range of clinical applications for this and other Trovagene assays.

"This first assay represents a significant milestone for Trovagene," said Antonius Schuh, Ph.D., chief executive officer of Trovagene. "Moving forward, our goal is to apply our technology for improved monitoring of tumor dynamics, leading to more effective management of cancer patients."

Trovagene has detected the BRAF V600E mutation in a variety of cancers, with   high levels of sensitivity and strong concordance with tissue biopsy. Further expansion of the company's monitoring capabilities will include additional mutational markers with known clinical utility, as well as known genomic alterations that indicate resistance to therapy.

The Trovagene cell-free BRAF test is now available to healthcare providers for patient testing.  Physicians interested in utilizing this test should contact Client Services at 888-391-7992. For more information, please visit

1 - Vultur A, Villanueva J, Herlyn M. Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clin Cancer Res 2011; 17(7):1658-63

About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is leveraging its patented technology for the detection of cell-free DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that can be isolated and detected from urine. Trovagene has a strong intellectual property asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2012 and other periodic reports filed with the Securities and Exchange Commission.


Trovagene, Inc.

Stephen Zaniboni
Chief Financial Officer
Trovagene, Inc.

SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Henry Schein Animal Health Launches Its First Veterinary Orthopedic Instrument Catalog
2. John Theurer Cancer Center Announces Positive Results from Revlimid MCL-001(EMERGE) Study Leading to FDA Approval of First Oral Therapy for Refractory Mantle-Cell Lymphoma (MCL) Patients
3. According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
4. Rubbermaid Commercial Products Debuts Industrys First Disposable Microfiber
5. DePuy Hip Recall Settlement News: First Federal Trial To Begin This Week
6. Hoopes Vision Surgeon First in Utah to Implant New Light Adjustable Artificial Lens
7. MR Solutions to Launch Two World Firsts in Pre Clinical Scanning at the World Molecular Imaging Conference in Savannah This Week - a Combined 3T, Cryogen Free MRI/PET and a 3T MRI/SPECT
8. Ventana receives approval from Chinas FDA for first fully automated IHC companion diagnostic identifying ALK protein expression in lung cancer patients
9. Quantum Materials Establishes Milestone as First Company to Deliver Tetrapod Quantum Dot Samples to LCD Display Manufacturer
10. Fluke Biomedical launches its first mobile app
11. Synthetic Biologics to Present at the First Global Life Sciences Conference in Warsaw, Poland
Post Your Comments:
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening to conquer ... in advanced audiology and hearing aid technology, has today ... world,s first internet connected hearing aid that opens up ...      (Photo: ) , ... , TwinLink™ - the first dual communication ...
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
(Date:6/23/2016)... FRANKLIN, Tenn. , June 23, 2016 ... for automating, integrating and transforming the patient ... launch of several innovative new products and ... depth of its revenue cycle offerings. These ... establish more efficient workflows, remain compliant in ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):